ArticleCell biochemistry and biophysics2026
Anthraflavic Acid Exerts Antimetastatic Effects on Human Non-Small-cell Lung Cancer Cells Via Activation of Aryl Hydrocarbon Receptor and Regulation of the JNK, p38, and c-myc Signaling Pathways.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Matrix metalloproteinases can degrade major extracellular matrix (ECM) components, thereby contributing to cancer metastasis. Reactive oxygen species (ROS) are closely related to the regulation of cancer metastasis. Here, we report that the polycyclic aromatic hydrocarbon compound anthraflavic acid (AFA), a derivative of anthraquinone, exerts an antimetastatic effect on human non-small-cell lung cancer (NSCLC) cells via ROS regulation. Molecular docking analysis indicated that AFA is a potential agonist for aryl hydrocarbon receptor (AHR). AFA stimulates transcriptional expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and reduces ROS level via AHR. AFA inhibits the cell migration/invasion and transcriptional expression of MMP-2 and MMP-9, two major gelatinases that can degrade gelatin, which is a major ECM component. The antimetastatic effects of AFA on A549 human NSCLC cells were reversed by hydrogen peroxide. This implies that the AFA exerts antimetastatic effects through ROS regulation via AHR-Nrf2. AFA also modulates p38, JNK, and c-myc signalings, which are closely related to cancer metastasis regulation. Our results suggest that AFA is a novel effective potential antimetastatic agent for patients with NSCLC.
Indexed as
Identifiers
41385169What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.